REPRIEVE: Pitavastatin to Prevent Cardiovascular Disease in HIV

HIV patients are known to have up to a two-fold increase in heart-related events, compared with the general population. Could treatment with statins reduce this risk? Dr. Steven Fine, an infectious disease specialist affiliated with the University of Rochester, reviews the recently published results of the REPRIEVE trial. The big picture is a 35% reduction in heart-related events. Dr. Fine digs into the details and statistics of the trial, and the encouraging results of statin treatment, even in those deemed to be at lower risk. Related Content: The Reprieve Trial  The Results in NE Journal of Medicine CEI toll free line for NYS providers: 866-637-2342 https://ceitraining.org/